TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31316786
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for diverticular disease
Study: 31317619
Drug: Opioid prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid prescription at discharge
Study: 31318125
Drug: Chemotherapy (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (20 patients, 51%)
Study: 31319038
Drug: LPS +
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS + ATP + P2X7 selective inhibitor
Study: 31319809
Drug: Functional autonomy
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional autonomy level change as assessed by the instrumental abilities of daily living (IADL) score
Study: 31319994
Drug: Afatinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (50 mg once daily) plus Ruxolitinib (25 mg twice daily)
Study: 31320352
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 21 days for 6 weeks after the final dose of BCG)
Study: 31320352
Drug: Pembrolizumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab and intravesicular BCG therapy
Study: 31320894
Drug: Electromagnetic Shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic Shock Wave Therapy
Study: 31321485
Drug: TNFi monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi monotherapy (existing use)
Study: 31321485
Drug: csDMARD monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARD monotherapy (existing use)
Study: 31321485
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (existing use)
Study: 31321485
Drug: TNFi monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi monotherapy (initiated use)
Study: 31321485
Drug: csDMARD monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARD monotherapy (initiated use)
Study: 31321485
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (initiated use)
Study: 31321631
Drug: DS-8500a 75
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 75 mg + single-dose rosuvastatin 10 mg
Study: 31321631
Drug: DS-8500a 75
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 75 mg + single-dose atorvastatin 10 mg
Study: 31323045
Drug: Duloxetine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (active medication)
Study: 31323705
Drug: REP 2139-Ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: REP 2139-Ca therapy
Study: 31324600
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg intravenous infusions over six 4-weekly cycles and ibrutinib 420 mg oral once per day for 9 months
Study: 31324600
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg oral once per day for 6 additional months (for patients with complete response and minimal residual disease <0.01%)
Study: 31324600
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg oral once per day plus fludarabine, cyclophosphamide, and obinutuzumab 1000 mg for 6 months (for patients with partial response or complete response with minimal residual disease ≥0.01%)
Study: 31325044
Drug: hsTnT undetectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT undetectable (<5 ng/L)
Study: 31325044
Drug: hsTnT normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT normal (5-14 ng/L)
Study: 31325044
Drug: hsTnT stable
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT stable elevated (15-51 ng/L)
Study: 31326957
Drug: Waterpipe tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waterpipe tobacco (WPT) smoking session with 10 g of WPT and 470 mL of water
Study: 31329313
Drug: Omalizumab +
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab + peanut oral immunotherapy (pOIT)
Study: 31329922
Drug: Pegfilgrastim 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 3.6 mg administered at least 24 h after cabazitaxel infusion
Study: 31329922
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m2 every 3 weeks, up to 10 cycles, with oral prednisolone 10 mg daily
Study: 31330556
Drug: 25 G fine-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 G fine-needle aspiration (FNA) followed by 20 G fine-needle biopsy (FNB)
Study: 31330556
Drug: 20 G fine-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G fine-needle biopsy (FNB) followed by 25 G fine-needle aspiration (FNA)
Study: 31331295
Drug: Olaratumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaratumab (60 mg/kg twice weekly) + mouse anti-PDGFRA antibody 1E10 (20 mg/kg twice weekly)
Study: 31331295
Drug: Doxorubicin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (3 mg/kg once weekly)
Study: 31331295
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of doxorubicin and anti-PDGFRA
Study: 31331701
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg/day) continuously until disease progression or unacceptable toxicity
Study: 31331701
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg/day)
Study: 31331917
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg once daily, lenalidomide, and rituximab
Study: 31332062
Drug: Nevirapine pharmacokinetics
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine pharmacokinetics (PK) evaluated during anti-TB therapy
Study: 31332062
Drug: Nevirapine pharmacokinetics
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine pharmacokinetics (PK) evaluated after completing anti-TB therapy
Study: 31332068
Drug: WCK 4282
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WCK 4282 (Cefepime-Tazobactam Combination)
Study: 31332649
Drug: Single-dose 12/400-µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 12/400-µg Formoterol/Budesonide combination
Study: 31333456
Drug: Chinese Herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Herbal Medicine combined with EGFR-TKI
Study: 31333511
Drug: Dextromethorphan as
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan as an add-on therapy to Methylphenidate
Study: 31334125
Drug: Topical Diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Diclofenac
Study: 31334546
Drug: Recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle-stimulating hormone (FSH) stimulation with a flexible antagonist protocol
Study: 31334635
Drug: AB680, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB680, a potent human CD73 inhibitor
Study: 31334925
Drug: Topical collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical collagen powder
Study: 31335117
Drug: NIR photoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR photoimmunotherapy (NIR-PIT) using IRdye700DX conjugated with a monoclonal antibody targeting cancer cell surface antigens.
Study: 31335321
Drug: CAR-T therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T therapy
Study: 31337344
Drug: Fluad® (adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluad® (adjuvanted inactivated trivalent influenza vaccine)
Study: 31338476
Drug: Nabilone (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (0.5-2 mg)
Study: 31338800
Drug: Dexlansoprazole 15
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole 15 mg every 12 hours (q12h) for 5 days
Study: 31338800
Drug: Dexlansoprazole 30
Normalized name: dexlansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 30 mg every 12 hours (q12h) for 5 days
Study: 31338800
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg every 12 hours (q12h) for 5 days
Study: 31340868
Drug: Sublingual microcirculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual microcirculation parameters in septic patients
Study: 31340982
Drug: Zanubrutinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib (various doses: 40, 80, 160, or 320 mg once daily or 160 mg twice daily)
Study: 31342851
Drug: Home-based telemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based telemental health therapy
Study: 31343665
Drug: Nivolumab (0.1-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (0.1-10.0 mg/kg) every 2 weeks in 8-week cycles for up to 96 weeks
Study: 31343665
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment with treatment-related AEs of any grade
Study: 31343665
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment with treatment-related AEs of grade 3 or more
Study: 31343665
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment without treatment-related AEs
Study: 31343665
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment with Eastern Cooperative Oncology Group performance status of 0
Study: 31343665
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment with liver metastases
Study: 31343665
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment with bone metastases
Study: 31345133
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid filtration (neurapheresis therapy) for up to 24 hours
Study: 31345133
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid filtration (neurapheresis therapy)
Study: 31345639
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of MMR-containing vaccine (Priorix or Priorix-Tetra)
Study: 31345639
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of MMR-containing vaccine (Priorix or Priorix-Tetra)
Study: 31345639
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of MMR vaccine given later in life
Study: 31345639
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of MMR vaccine given anytime over the 10-year period
Study: 31345970
Drug: Known atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Known atrial fibrillation (AF) patients not treated with oral anticoagulation
Study: 31346927
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg plus erlotinib
Study: 31346927
Drug: Ipilimumab 1
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 1 mg/kg plus erlotinib
Study: 31347100
Drug: MDI (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI (multiple daily injections of insulin)
Study: 31348866
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for LOM after ACL reconstruction
Study: 31348987
Drug: Dance/Movement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance/Movement Therapy
Study: 31349866
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg oral dispersible tablet)
Study: 31349866
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to zinc tablet)
Study: 31350082
Drug: Bioinductive collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioinductive collagen implant for rotator cuff repair
Study: 31350201
Drug: Capecitabine/Oxaliplatin regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine/Oxaliplatin regimen (capecitabine 825 mg/m2) with concurrent radiotherapy (RT)
Study: 31350241
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during the periconception period and pregnancy.
Study: 31350244
Drug: SCD assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCD assessment including clinical and neuropsychological assessments, blood sample collection for plasma beta-amyloid and ApoE genotype, urine samples collection for AD7c-NTP, multimodal MRI scans, glucose metabolism and amyloid positron emission tomography.
Study: 31350306
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) monotherapy (1.8 mg/kg IV every 3 weeks up to 8 cycles)
Study: 31350306
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) monotherapy
Study: 31351076
Drug: Mechanical Insufflation-Exsufflation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical Insufflation-Exsufflation (MI-E) titration
Study: 31351267
Drug: Recommended targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended targeted treatment (RTT)
Study: 31351862
Drug: AMP-224 with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP-224 with SBRT (8 Gy on day 0) and cyclophosphamide (200 mg/m2)
Study: 31351922
Drug: 0.67 mg
Normalized name: petrolatum 0.67 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.67 mg GLS-5300
Study: 31351922
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg GLS-5300
Study: 31351922
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg GLS-5300
Study: 31351922
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of GLS-5300
Study: 31352425
Drug: ePIPAC-OX (92
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePIPAC-OX (92 mg/m²)
Study: 31352850
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2
Study: 31354330
Drug: Hydrocortisone self-administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone self-administration
Study: 31354810
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D
Study: 31354810
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg/daily) plus placebo
Study: 31354960
Drug: Personalized eHealth
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized eHealth intervention with daily goals via ExSed application for 90 days after discharge.
Study: 31355926
Drug: Satisfactory AFP
Normalized name: OCTINOXATE 0.28 g in 4 g TOPICAL LIPSTICK [SATIN SATISFACTION LIP COLOR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satisfactory AFP decline (AFP normalized within the first 2 measures after chemotherapy)
Study: 31355926
Drug: Unsatisfactory AFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsatisfactory AFP decline (AFP half-life >7 days after chemotherapy)
Study: 31356140
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle)
Study: 31356143
Drug: TAA-Ts (Tumor-associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA-Ts (Tumor-associated antigen cytotoxic T cells) infused at three dose levels: 1, 2, and 4 × 10^6 cells
Study: 31356143
Drug: TAA-Ts at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA-Ts at the highest dose level
Study: 31356143
Drug: Prior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior therapy (control)
Study: 31357748
Drug: 5-FU/LV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV combination therapy
Study: 31358485
Drug: Bortezomib (BTZ)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (BTZ) administered at peak G-CSF mobilization
Study: 31358485
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered for 5 days
Study: 31359361
Drug: quizartinib 20
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: quizartinib 20 mg/day
Study: 31359361
Drug: quizartinib 30
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: quizartinib 30 mg/day
Study: 31359361
Drug: quizartinib 60
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: quizartinib 60 mg/day
Study: 31359874
Drug: Sustained virological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained virological response (SVR) using direct-acting antiviral therapies
Study: 31362654
Drug: Gene correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene correction strategies (e.g., suppression of BCL11A, HPFH, zinc-finger nucleases)
Study: 31364010
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13), two doses 8 weeks apart
Study: 31364010
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (PPV23), one dose
Study: 31364233
Drug: Flexible BI/GLP-1RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible BI/GLP-1RA combination
Study: 31364233
Drug: Fixed BI/GLP-1RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed BI/GLP-1RA combination
Study: 31364457
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM), specifically Salvia miltiorrhiza, administered intravenously to 74.7% of patients.
Study: 31364457
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) use in hospitals (99.4% of hospitals used TCM).
Study: 31364601
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - weekly email newsletter on HIV topics excluding ART adherence for 5 months
Study: 31367468
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks until no evidence of fluid, then 2 mg every 8 weeks
Study: 31367538
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² and sirolimus (oral daily after loading dose)
Study: 31367691
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet with 1 Hass avocado daily
Study: 31368034
Drug: Taselisib (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib (2-6 mg tablet or 3-6 mg capsule) plus docetaxel
Study: 31368034
Drug: Taselisib (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib (2-6 mg tablet or 3-6 mg capsule) plus paclitaxel
Study: 31368720
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment for eating disorders with a focus on trauma work, fostering patient agency, and relational dynamics in patient-therapist dyad.
Study: 31369089
Drug: rhPTH(1-84) 25
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum
Study: 31369217
Drug: Biological motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological motion (dynamic light point walking human or cat) versus nonbiological motion (scrambled controls)
Study: 31370978
Drug: Past month
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past month injection drug use
Study: 31371191
Drug: Rivaroxaban treatment
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban treatment in patients with WRF
Study: 31371191
Drug: Rivaroxaban treatment
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban treatment in patients with SRF